About | Free Trial

Last Update

2016-04-12T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Thomas Neenan?

Dr. Thomas Neenan X. PhD

Chief Technology Officer

Sideris Pharmaceuticals Inc

Direct Phone: (339) ***-****       

Email: t***@***.com

Sideris Pharmaceuticals Inc

91 Hartwell Avenue

Lexington, Massachusetts 02421

United States

Company Description

Sideris Pharmaceuticals is an independent biopharmaceutical company focused on the development of treatments for diseases of iron overload, including conditions involving maintenance transfusion therapy. Sideris' lead clinical candidate, SP-420, has the ... more

Find other employees at this company (5)

Background Information

Employment History

Chief Scientific Officer
Sun BioPharma Inc

Vice President, Business Development
Proxy Biomedical Ltd

Vice President, Business Development, The Americas
Warwick Effect Polymers Ltd

Founder and Chief Executive Officer
Viscus Biologics

Vice President, Business Operations
Genzyme Corporation

Vice President of New Technology Development
GelTex Pharmaceuticals , Inc.

Vice President, Business Operations
GelTex Pharmaceuticals , Inc.

Affiliations

Post-Doctoral Fellow
Harvard University

Education

B.Sc
chemistry
University College Dublin of the National University of Ireland

B.Sc.

University College Dublin

Ph.D
Synthetic Chemistry
Penn State University

Ph.D.
chemistry
The Pennsylvania State University

Web References (36 Total References)


Leadership – Sun BioPharma

www.sunbiopharma.com [cached]

Thomas X. Neenan, Ph.D. Co-Founder and Chief Scientific Officer

Dr. Neenan is an entrepreneur and scientist with extensive chemistry and business development executive experience with AT&T Bell Labs, Geltex, Genzyme, Trine Pharma, Warwick Effect Polymers, Gelesis and Proxy Biomedical. Dr. Neenan most recently served as Founder and Chief Technology Officer of Sideris Pharmaceuticals Inc, raising $32M in equity financing in 2013 Dr. Neenan holds a B.Sc (Hons) in Chemistry and Math from the University College Dublin in Ireland, a Ph.D in Synthetic Chemistry from Penn State University, and post-doctoral studies in chemistry at Harvard University. Dr. Neenan also brings a wealth of knowledge to the Company on drug manufacture and was instrumental in improving the synthetic process for SUN-101. He is the author of approximately 60 publications in the fields of chemistry and materials sciences and holds approximately 40 US and international patents.


Board of Directors – Sun BioPharma

www.sunbiopharma.com [cached]

Thomas X. Neenan, Ph.D., Co-Founder, Chief Scientific Officer. Dr. Neenan is an entrepreneur and scientist with extensive chemistry and business development executive experience with AT&T Bell Labs, Geltex, Genzyme, Trine Pharma, Warwick Effect Polymers, Gelesis and Proxy Biomedical. Dr. Neenan most recently served as Founder and Chief Technology Officer of Sideris Pharmaceuticals Inc, raising $32M in equity financing in 2013 Dr. Neenan holds a B.Sc (Hons) in Chemistry and Math from the University College Dublin in Ireland, a Ph.D in Synthetic Chemistry from Penn State University, and post-doctoral studies in chemistry at Harvard University. Dr. Neenan also brings a wealth of knowledge to the Company on drug manufacture and was instrumental in improving the synthetic process for SUN-101. He is the author of approximately 60 publications in the fields of chemistry and materials sciences and holds approximately 40 US and international patents.


Dr. Thomas ...

www.gulfcoastchallenge.org [cached]

Dr. Thomas Neenan

...
Thomas Neenan
Dr. Neenan is currently the Chief Scientific Officer of Sun BioPharma. Prior to his work with Sun BioPharma, Dr. Neenan served as the Founder and CTO of Sideris Pharmaceuticals, a clinical stage developer of small molecules for the treatment of disease of iron overload. Dr. Neenan founded the company in 2012, raised $32M in equity financing and completed an option agreement with Novartis to acquire to the company following Phase 2 studies. Prior to Sideris, Dr. Neenan served as Founder and CEO of Viscus Biologics, Cleveland Ohio. Prior to Viscus, Dr. Neenan served in senior management roles at Proxy Biomedical (Galway, Ireland), Warwick Effect Polymers (Coventry, UK) and Trine Pharmaceuticals. Previously, he served as Vice-President, Business Operations for Genzyme Drug Discovery and Development. He received his B.Sc. (Hons) from University College Dublin, his Ph.D. in chemistry from The Pennsylvania State University, and was a post-doctoral Fellow at Harvard University.


Leadership | Sun BioPharma

www.sunbiopharma.com [cached]

Thomas X. Neenan, Ph.D., Co-Founder, Chief Scientific Officer and Member of the Board of Directors. Dr. Neenan is an entrepreneur and scientist with extensive chemistry and business development executive experience with AT&T Bell Labs, Geltex, Genzyme, Trine Pharma, Warwick Effect Polymers, Gelesis and Proxy Biomedical. Dr. Neenan most recently served as Founder and Chief Technology Officer of Sideris Pharmaceuticals Inc, raising $32M in equity financing in 2013 Dr. Neenan holds a B.Sc (Hons) in Chemistry and Math from the University College Dublin in Ireland, a Ph.D in Synthetic Chemistry from Penn State University, and post-doctoral studies in chemistry at Harvard University. Dr. Neenan also brings a wealth of knowledge to the Company on drug manufacture and was instrumental in improving the synthetic process for SUN-101. He is the author of approximately 60 publications in the fields of chemistry and materials sciences and holds approximately 40 US and international patents.


KSLSF

kslsfund.com [cached]

Thomas X. Neenan Ph.D.

Dr. Neenan is a Boston based entrepreneur whose most recent venture was as Founder and CTO of Sideris Pharmaceuticals Inc., a developer of novel chelators for the treatment of diseases of iron overload. Sideris raised $32M in equity financing and completed an option deal worth up to $300M with Novartis Pharmaceuticals in Oct. 2013. Prior to Sideris, Dr. Neenan served in founder or senior management role at several materials and polymer focused companies including Viscus Biologics LLC (xenografts), Proxy Biomedical (Galway, Ireland) (polymeric surgical materials), Warwick Effect Polymers (Coventry, UK) (controlled free radical polymerization for consumer and biomedical applications) and Trine Pharmaceuticals (gastrointestinal drugs). Previously, Dr. Neenan held positions of increasing responsibility, including Vice-President of New Technology Development at Geltex Pharmaceuticals, a polymer drug company acquired by Genzyme for $1.1B. Dr. Neenan holds a B.Sc (Hons) from University College Dublin. He received his Ph.D. in inorganic chemistry from the Pennsylvania State University, and was a Fellow at Harvard University. He is the author of 60+ publications and holds 40+ US and international patents. Dr. Neenan currently serves on the Board of Directors of Sun BioPharma Inc., a privately financed pancreatic oncology company, and as an advisor to Quad Technologies Inc., a development stage company specializing in cell and protein separations science.

Similar Profiles

Other People with this Name

Other people with the name Neenan

Gerald Neenan
Neal & Harwell , PLC

Victoria Neenan
VF Corporation

Colleen Neenan
ARCADIS N.V

Caoilfhionn Neenan
DB Schenker Limited

Erik Neenan
Qi Consulting , LLC

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory